Posting fresh info about MS, for people with MS and their supporters

  • EX-US: First Oral Approved for PWMS: Cladribine approved in RUSSIA

    Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the Russian Federal Service on Surveillance in Healthcare and Social Development has become the first [...]

    • Merck Refiles Cladribine for US Approval

      FRANKFURT (Dow Jones)–German pharmaceutical and chemicals company Merck KGaA (MRK.XE) said Tuesday it resubmitted its application for U.S. regulatory approval of oral multiple sclerosis treatment cladribine–seven months [...]

      • Merck KGaA Submits Application For Cladribine Tablets In US

        Germany’s Merck KGaA has made further progress in its bid to be the first company to market an oral multiple sclerosis treatment by filing cladribine in the [...]

        • Hot off the ECTRIMS Press…Cladribine Reduces Disease Activity in a Big Way

          Darmstadt, Germany, September 11, 2009 – Merck KGaA announced today new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using a [...]

          • Merck Sumbits Cladribine Application for EU Approval

            July 23, 2009 — 9:05am ET | By John Carroll Racing to beat Novartis to the world’s biggest drug markets with a new oral therapy for multiple sclerosis, [...]

            • Hot off the ENS Press: Cladribine Is Safe Overall in Patients With Multiple Sclerosis

              MILAN, Italy — June 24, 2009 — According to a safety analysis of a study presented here at the 19th Meeting of the European Neurological Society (ENS), [...]

              • Hot off the AAN Press: Cladribine Reduces Relapses, Disability, Disease Progression

                April 29, 2009 Merck KGaA on Wednesday presented detailed results from a previously announced Phase III study of investigational oral multiple sclerosis drug cladribine at the American [...]

                • LATE BREAKING: New Phase III Data for Cladribine to be Presented at AAN

                  CLARITY (CLAdRIbine tablets Treating MS OrallY) Study Data to be Presented as Late-Breaking Oral Presentation By: PR Newswire Mar. 30, 2009 08:01 AM GENEVA, Switzerland, March 30 [...]

                  • The Age of Orals: Who Will Win the Race to the Market?

                    Jan 23, 2009 Oral Cladribine Reduces MS Relapses in Phase 3 Clinical Trial Oral cladribine (EMD Serono) reduced the relapse rate significantly more than inactive placebo in [...]



SUPPORT / Find out More



aan, alemtuzumab, avonex, betaseron, biogen, bioms medical corp, campath, ccsvi, cis, cladribine, clarity, cognitive dysfunction, copaxone, daclizumab, dirucotide, discovery, ectrims, elan, fampridine-sr, fatigue, fda, fda fast track status, fingolimod, fty-720, genzyme, gilenia, gilenya, interferons, laquinimod, merck, merck/serono, novartis, oral ms therapies, phase iii, pml, rebif, rrms, serono, smoking, spms, stem cells, teriflunomide, teva, therapy, tysabri


Follow me on Twitter
Friend me on Facebook
Subscribe by Email

Bookmark and Share

Wordpress Engine. Upstart Theme. Better Project.